Show simple item record

dc.contributor.authorLorber, Barbara
dc.contributor.authorTassoni, Alessia
dc.contributor.authorBull, Natalie D
dc.contributor.authorMoschos, Marilita M
dc.contributor.authorMartin, Keith
dc.date.accessioned2012-07-25T19:15:51Z
dc.date.available2012-07-25T19:15:51Z
dc.date.issued2012-06-06
dc.identifier.issn1471-2202
dc.identifier.urihttp://www.dspace.cam.ac.uk/handle/1810/243508
dc.description.abstractBACKGROUND: We have previously shown that the slow Wallerian degeneration mutation, whilst delaying axonal degeneration after optic nerve crush, does not protect retinal ganglion cell (RGC) bodies in adult rats. To test the effects of a combination approach protecting both axons and cell bodies we performed combined optic nerve crush and lens injury, which results in both enhanced RGC survival as well as axon regeneration past the lesion site in wildtype animals. RESULTS: As previously reported we found that the Wld(S) mutation does not protect RGC bodies after optic nerve crush alone. Surprisingly, we found that Wld(S) transgenic rats did not exhibit the enhanced RGC survival response after combined optic nerve crush and lens injury that was observed in wildtype rats. RGC axon regeneration past the optic nerve lesion site was, however, similar in Wld(S) and wildtypes. Furthermore, activation of retinal glia, previously shown to be associated with enhanced RGC survival and axon regeneration after optic nerve crush and lens injury, was unaffected in Wld(S) transgenic rats. CONCLUSIONS: RGC axon regeneration is similar between Wld(S) transgenic and wildtype rats, but Wld(S) transgenic rats do not exhibit enhanced RGC survival after combined optic nerve crush and lens injury suggesting that the neuroprotective effects of lens injury on RGC survival may be limited by the Wld(S) protein.
dc.languageEnglish
dc.language.isoen
dc.publisherSpringer Science and Business Media LLC
dc.titleRetinal ganglion cell survival and axon regeneration in WldS transgenic rats after optic nerve crush and lens injury.
dc.typeArticle
dc.date.updated2012-07-25T19:15:51Z
dc.description.versionRIGHTS : This article is licensed under the BioMed Central licence at http://www.biomedcentral.com/about/license which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display the work; make derivative works; or make commercial use of the work - under the following conditions: the original author must be given credit; for any reuse or distribution, it must be made clear to others what the license terms of this work are.
dc.rights.holderBarbara Lorber et al.; licensee BioMed Central Ltd.
prism.publicationDate2012
prism.publicationNameBMC Neurosci
dcterms.dateAccepted2012-06-06
rioxxterms.versionofrecord10.1186/1471-2202-13-56
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2012-06-06
dc.contributor.orcidMartin, Keith [0000-0002-9347-3661]
dc.identifier.eissn1471-2202
rioxxterms.typeJournal Article/Review
pubs.funder-project-idWellcome Trust (079249/Z/06/H)
cam.issuedOnline2012-06-06


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record